NOVO NORDISK : Bernstein remains Neutral

Published on 06/12/2025 at 02:58

MarketScreener with dpa-AFX Analyser

Bernstein confirms his opinion on the stock and remains Neutral. The target price continues to be set at DKK 620.

Latest news about Novo Nordisk A/S

Fangzhou Inc. and Novo Nordisk Signs Collaboration Memorandum to Establish A New Ecosystem for Health Management	Jul. 18	CI
NOVO NORDISK : UBS keeps its Buy rating	Jul. 18	ZD
NOVO NORDISK : Deutsche Bank reaffirms its Buy rating	Jul. 18	ZD
Many US employers plan to pare health benefits as weight-loss spending soars	Jul. 17	RE
Gerresheimer calls a halt to discussions on potential takeover	Jul. 16	RE
Gerresheimer calls a halt to discussions on potential takeover	Jul. 16	RE
Biocon eyes generic Wegovy obesity drug launch in India, Canada in next 2 years, CEO says	Jul. 16	RE
NOVO NORDISK : UBS lowers target price	Jul. 16
Berenberg Keeps Novo Nordisk at Hold Amid Wegovy Volume Growth Data Focus	Jul. 16	MT
NOVO NORDISK : Receives a Buy rating from UBS	Jul. 16	ZD
European shares fall on healthcare, financials drag; focus on US-EU trade deal	Jul. 15	RE
European shares fall on healthcare, financials drag; focus on US-EU trade deal	Jul. 15	RE
Kailera touts late-stage win for weight-loss drug in China	Jul. 15	RE
Indutrade: Life Science Achieved Positive Organic Growth Excluding Novo Nordisk Sales	Jul. 15	FW
NOVO NORDISK : Berenberg sticks Neutral	Jul. 15	ZD
Carnegie Strategy Fund Down 0.44% in June — New Investments in Novo Nordisk and SKF	Jul. 14	FW
Clever Culture Says Novo Nordisk to Assess Its APAS Technology for Use Across Manufacturing Network	Jul. 14	MT
Clever Culture Systems says receipt of purchase order for an APAS Independence instrument from Novo Nordisk in Europe	Jul. 13	RE
European stocks down with bank and healthcare drag, US-EU tariffs in focus	Jul. 11	RE
FDA May Fast Track Drug Reviews for Lower US Prices	Jul. 11	MT
FDA May Fast Track Drug Reviews for Lower US Prices, Bloomberg Reports	Jul. 11	MT
NOVO NORDISK : Gets a Buy rating from UBS	Jul. 11	ZD
Wall Street Waits to Hear the Numbers	Jul. 11
Mining, healthcare prop up European shares; US-EU trade talks in focus	Jul. 10	RE
Major deals involving U.S. drugmakers and biotechs over the past decade	Jul. 09	RE